{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:14:56Z","timestamp":1770416096117,"version":"3.49.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"Charleston Laboratories"},{"name":"This article was sponsored by Daiichi Sankyo Co., Ltd, Tokyo, Japan."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2017,10,3]]},"DOI":"10.1080\/00325481.2017.1345282","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T10:52:42Z","timestamp":1498042362000},"page":"698-708","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["The effects of food on opioid-induced nausea and vomiting and pharmacological parameters: a systematic review"],"prefix":"10.1080","volume":"129","author":[{"given":"Robert B.","family":"Raffa","sequence":"first","affiliation":[{"name":",","place":["USA"]},{"name":"University of Arizona College of Pharmacy, Tucson, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Colucci","sequence":"additional","affiliation":[{"name":"Colucci & Associates LLC, Newtown, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph V.","family":"Pergolizzi","sequence":"additional","affiliation":[{"name":"Naples Anesthesia and Pain Associates - Pain Medicine, Naples, FL, USA"},{"name":"NEMA Research Inc. \u2013 Experian, Naples, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,7,14]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_3_2_3_1","unstructured":"Centers for Disease Control and Prevention. New CDC Opioid Prescribing Guidelines: improving the Way Opioids are Prescribed for Safer Chronic Pain Treatment. [cited 2016 May 27]. Available from: http:\/\/www.wha.org\/pdf\/CDCguidelines_factsheet_opioids.pdf."},{"key":"e_1_3_2_4_1","unstructured":"US Food and Drug Administration. Fact sheet\u2014FDA opioids action plan. [cited 2016 Apr 11]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/FactSheets\/ucm484714.htm"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31818164f2"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0182"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2011.0069"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00983.x"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68700-X"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X1103900506"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeq323"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmn.2012.07.004"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2007.02.006"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.019"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.02920.x"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003783747"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.02.007"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.674499"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(99)00085-8"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0161"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M520"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31820d9b76"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0238"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03689.x"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31802b582f"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2010.0063"},{"key":"e_1_3_2_27_1","first-page":"615","article-title":"Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain","volume":"18","author":"Anastassopoulos KP","year":"2012","unstructured":"Anastassopoulos KP, Chow W, Tapia CI, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manage Care Pharm: JMCP. 2012;18:615\u2013626.","journal-title":"J Manage Care Pharm: JMCP"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2012.0151"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000164099.92112.29"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"e_1_3_2_31_1","unstructured":"FDA Briefing Document (Purdue Pharma L.P.): Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. 2015. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM461407.pdf\u00a0(accessed June 15 2017)"},{"key":"e_1_3_2_32_1","unstructured":"FDA Briefing Document (Collegium Pharmaceutical Inc). Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee. 2015. Available from: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM461639.pdf\u00a0(accessed June 15 2017)"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12628"},{"key":"e_1_3_2_34_1","volume-title":"Guidance for Industry: bioavailability and Bioequivalence Studies","year":"2002","unstructured":"Guidance for Industry: bioavailability and Bioequivalence Studies. 2002. Available from: https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3995B1_07_GFI-BioAvail-BioEquiv.pdf (accessed July 9, 2017)"},{"key":"e_1_3_2_35_1","volume-title":"Guidance for Industry: bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations","year":"2014","unstructured":"Guidance for Industry: bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations. 2014. Available from: https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm389370.pdf (accessed July 9, 2017)"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0032-y"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S70831"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S24372"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-7-2"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S64261"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.12.007"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.013"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0171"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S15133"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.05.009"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201764"},{"key":"e_1_3_2_47_1","article-title":"Oral human abuse potential of oxycodone DETERx(R) (Xtampza(R) ER)","author":"Kopecky EA","year":"2016","unstructured":"Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx(R) (Xtampza(R) ER). J Clin Pharmacol. 2016;57(4):500\u2013512. Epub 2016\/09\/28.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010383858"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0074-x"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.177"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S79499"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31816b58eb"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1526-5900(03)00556-X"},{"key":"e_1_3_2_54_1","first-page":"1347","article-title":"Management of common opioid-induced adverse effects","volume":"74","author":"Swegle JM","year":"2006","unstructured":"Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347\u20131354.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_55_1","volume-title":"HYSINGLA ER [prescribing information]","year":"2014","unstructured":"HYSINGLA ER [prescribing information]. Stamford (CT): Purdue Pharma LP; 2014."},{"key":"e_1_3_2_56_1","volume-title":"EMBEDA [prescribing information]","year":"2009","unstructured":"EMBEDA [prescribing information]. Bristol (TN): King Pharmaceuticals, Inc; 2009."},{"key":"e_1_3_2_57_1","volume-title":"TARGINIQ ER [prescribing information]","year":"2014","unstructured":"TARGINIQ ER [prescribing information]. Stamford (CT): Purdue Pharma LP; 2014."},{"key":"e_1_3_2_58_1","volume-title":"MORPHABOND [prescribing information]","year":"2015","unstructured":"MORPHABOND [prescribing information]. Valley Cottage (NY): Inspirion Delivery Technologies LLC; 2015."},{"key":"e_1_3_2_59_1","volume-title":"ZOHYDRO ER [prescribing information]","year":"2016","unstructured":"ZOHYDRO ER [prescribing information]. Morristown (NJ): Pernix Therapeutics, LLC; 2016."},{"key":"e_1_3_2_60_1","volume-title":"ARYMO ER [prescribing information]","year":"2017","unstructured":"ARYMO ER [prescribing information]. Wayne (PA): Egalet US Inc.; 2017."},{"key":"e_1_3_2_61_1","volume-title":"VANTRELLA ER [prescribing information]","year":"2017","unstructured":"VANTRELLA ER [prescribing information]. North Wales (PA): Teva Pharmaceuticals USA, Inc; 2017."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/187103"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/gm187"},{"issue":"11","key":"e_1_3_2_64_1","first-page":"S288","article-title":"Quantifying the impact of drug-drug interactions associated with opioids","volume":"17","author":"Pergolizzi JV","year":"2011","unstructured":"Pergolizzi JV. Quantifying the impact of drug-drug interactions associated with opioids. Am J Manag Care. 2011;17(Suppl 11):S288\u2013S292. Epub 2011\/10\/26.","journal-title":"Am J Manag Care"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2017.1345282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:31:08Z","timestamp":1770377468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2017.1345282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,14]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10,3]]}},"alternative-id":["10.1080\/00325481.2017.1345282"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2017.1345282","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}